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Abstract
The HIV/AIDS disease represent a priority for all health authorities in all countries and it also represents serious
added socioeconomic problems for societies over the world. The aim of this paper is to analize the economic
impact associated to the HIV/AIDS in an European context. We conducted a systematic literature review for five
different countries (France, Germany, Italy, Spain and United Kingdom) and searched five databases. Three types
of analyses were undertaken: descriptive statistics; quantitative analysis to calculate mean costs; and comparison
across countries. 26 papers were included in this study containing seventy-six cost estimates. Most of the studies
analyzed the health care cost of treatment of HIV/AIDS. Only 50% of the cost estimates provided mean lymphocyte
count describing the patients’ disease stage. Approximately thirty percent of cost estimates did not indicate the
developmental stage of the illness in the patients included. There is a high degree of variability in the estimated
annual cost per patient of the treatments across countries. There is also a great disparity in total healh care costs for
patients with lymphocyte counts between 200CD4+/mm3 and 500 CD4/mm3, although the reason of variation is
unclear. In spite of the potential economic impact in terms of productivity losses and cost of formal and informal
care, few studies have set out to estimate the non-medical costs of HIV/AIDS in the countries selected. Another
important result is that, despite the low HIV/AIDS prevalence, its economic burden is very relevant in terms of the
total health care costs in this five countries. This study also shows that there are relatively few studies of HIV costs
in European countries compared to other diseases. Finally, we conclude that the methodology used in many of the
studies carried out leaves ample room for improvement and that there is a need for these studies to reflect the
economic impact of HIV/AIDS beyond health care including other components of social burden.
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Background
Since the human immunideficiency virus discovery at the
beginning of the 80s and its manifestation in the human
immunideficiency, it was evident that this could become
one of the bigger problems of the XX century [1]. The
HIV/AIDS disease not only had and is having a high im-
pact on populations’ health but it represents serious added
socioeconomic problems for individuals, families, commu-
nities and governments of many countries [2-6].
Although high activity antiretroviral treatment (HAART)
supposed a radical treatment in the therapy for the HIV/
AIDS, they are not exempt of problems. Since a while ago,
there exists cientific evidence of the advers events (gastro-
intestinal problems, metabolic alterations, nefro-hepatic
problems, etc.) present in a high percentage of patients
[7-14]. Another important question is that,though the AIDS
phase is not developed, the virus atac at the defense level
provoques that a high percentage HIV + people are co-
infected by the hepatitis C [15]. On another hand, not
always the treatments are succesful in controlling the viral
burden and the best answer from the CD4 cells, though this
is one of the aspects that clearly shows the improvements
in the last year therapies [16-19].
In the OMS Europe region, which comprises all countries
that belong to Europe, counted down 2,800 deaths during
2008 due to the HIV/AIDS. Since the beginning of the
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epidemia till 2008, 342,768 people have been diagnosed
with AIDS in that region. This implies that around 150,000
people with this diagnostic lived in that area at that time,
from 49 countries out of 57 which have reported informa-
tion about the acumulated HIV/AIDS cases. The number
of incident cases was 5,218 people only from those coun-
tries belonging to the EU (excluding Austria, Denmark and
liechtenstein, for which there were not data available) being.
Estonia, Letonia, Portugal and Spain the fourth country
with the highest incidence rate. In Europa, the main cause
of transmission of new cases was the heterosexual contact
whereas in the EU, the main cannal of transmission was the
sex among men, with 40% of new cases, followed by the het-
erosexual contact (29% of cases) and drugs users (6%), being
classified 24% of cases by unknown originated cause [20].
HIV is a priority for all health authorities in all countries
over the world as one of the main dangers for individuals
health. Although the situation for developed and develop-
ing countries is quite different, this disease generates quite
a lot of pressure in the Health System according to the
amount of resources needed. This implies quite a lot of
relevant questions for decision makers.
Although economic evaluations of HAART have revealed
being a cost-effective treatment compared to the treatments
before [21,22], this does not really imply that the cost of
these treatments does not worry the decision makers.
Indeed, the appearance of new and more expensive drugs
highlights the importance for decision makers to study and
put more effort into the resources assignation due to the
spread of costs generated. The HAART treatment is not
considered the solution of this disease, but has increased
considerably the expectancy and quality of life from sero-
positive persons.
From the economic point of view, the introduction of the
HAART has supposed an increase in the total treatment
cost. Not really because the annual cost of treating is more
expensive but because the increase on the life expectancy
in patients [12,22-25]. The cost of treating a patient along
their life period notably increases [5,26]. However, unlike
what happens with other diseases such as ischemic heart
disease, stroke, mental illness or Alzheimer's disease, there
are few studies of HIV costs in European countries. So, im-
portant doubts still existing regarding the annual treatment
costs per patient and the heterogeneity of these costs
among the different European countries and the impact of
those on the health budget. In addition, it is also an element
of interest the distribution of the total healthcare costs
and the patient cost according the disease stage and the
defences (lymphocytes) level across patients.
However, it is also important to highlight that new treat-
ments have produced a relevant change on the job market
incorporation of these disease carriers. In a recent paper [6]
comparing the studies carried out in high income countries
in the 90s decade with those where the HAART use was
extended, there were extensive differences regarding the
impact in terms of job market. More precisely, studies
carried out during the 80s and early 90s in high-income
countries pointed out that an HIV diagnosis had a strong
impact on labour force participation [27-30]. The thera-
peutic advances made since the mid 90s have substantially
changed this panorama improving the labour participation
of HIV + persons [6,31-35].
Despite the improvement in the participation on the job
market on recent years, still important the economic im-
pact and social cost acrued in these population group. The
accumulated HIV/AIDS cases, the negative consecuences
for health, and the high treatment cost remark this area as
a primary objective for all governments across countries.
A global review on the cost of HIV stressed the need to
increase the evidence published to more accurately estimate
the impact of the overall cost of HIV infection/AIDS [3].
The results from this review demonstrates the great effort
and interest embodied in the overall estimate of costs of
this disease in this last decade in five European countries.
The aim of this paper is to analyze the health care
(hospitalization; antiretrovirals and other drugs; laboratory
tests; specialists and GP consultations; and others) and non
health care (productivity losses and formal and informal
care) resources associated to the HIV treatment in an
European context. The added value of this new review on
HIV costs is the quantitative analysis using cost estimates
for five different countries in Europe, allowing for compari-
sons among them. This imply to compare treatment and
social costs associated to HIV across European countries.
Methods
The systematic literature review was conducted for five dif-
ferent countries: Spain, Germany, France, Italy and United
Kingdom. Five databases (Health Economic Evaluations
Database (HEED), NHS Economic Evaluation Database
(NHS EED), Health Tecnology Assessment (HTA), MED-
LINE Ovid and PubMed, and ECONLIT) were searched
from their inception to September 2010 using key words:
(cost* or economic* or valu* or pharmac* or impact or bur-
den or drug or expenditure* or willingness or employment
or resource* or use* or utilization) crossed with (HIV* or
AIDS or antirretroviral therapy) in HEED; and, (HIV* or
AIDS or antirretroviral therapy) for the NHS EED and
HTA searches. In addition, a search in MEDLINE Ovid and
Pubmed, and ECONLIT was undertaken with no relevant
results, therefore all results from these three databases were
desestimated. The search terms used were in English. The
search was limited to papers related to humans and no time
restriction was applied, thought all papers published after
the introduction of the HAART were excluded. Papers in
English and Spanish of cost-of illness giving information of
the healthcare and non-healthcare costs were included.
Papers were excluded if they: were economic evaluations of
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HIV/AIDS due to the differences of methodology across
studies; were review articles; did not calculate the costs for
any of the countries of interest for this study; did not
contribute information of interest; were published before
1996, when HAART were introduced, dut to the impact
on treatment costs they had. Review articles were disre-
gard to avoid duplication of the same estimates in the
quantitative analysis. We assume that all cost estimates
included in the different review papers were identified by
the the systematic literature review conducted in this
paper. If there are more than one cost estimate by paper,
all of them will be included in the analysis, generating
more than one cost estimate by paper. Therefore, there is
the possibility of ending with more cost estimates than
papers reviewed. These cost estimates will be the base for
the quantitative analysis of this paper. Details of this to
follow.
A data extraction form included questions on: context
(e.g. geographical study location), sampling and character-
istics of sample (e.g. HIV/AIDS disease level), methods
and results (e.g. type of costs analysis, year of prices, costs
sources) and conclusions of the studies (e.g. results sum-
mary). Each abstract and paper selected was reviewed.
Three types of analyses were undertaken. First, sum-
mary descriptive statistics were used to describe the back-
ground (e.g. country, level of HIV/AIDS disease) and type
of costs. Further quantitative analysis was based on the
cost estimates reported by the papers including healthcare
and non-healthcare costs. Average costs were calculated
for each country according to the estimated resulting from
the systematic literature review. Secondly, mean, standard
deviations, 95% confident interval values calculated using
STATA v9 were used to summarise mean costs and
thirdly, comparison across countries was carried out. The
average costs results provided by the papers and therefore
results from this analysis rely on methods of calculation
from each paper.
To aid comparative quantitative analysis, estimated costs
were converted to €2010 using country-specific gross do-
mestic product deflators [36] and World Bank purchasing
power parities (PPP) [37]. Estimated costs values were
multiplied by the coefficient of gross domestic product
(GDP) for 2010 divided by the GDP of the particular year
of the study, and then divided by the PPP conversion factor
for 2010. If required, the exchange rates applied were from
the European Central Bank, 2010. For those papers not
reporting the year when the costs were calculated for, the
publication was used. Those papers reporting the price
along a two year interval (e.g. 1995–1996) the most recent
year was used to update prices. In addition, to calculate
the percentage that would involve treatment of HIV/AIDS
out of the total healthcare expenditure, prevalence data -
number of people who live with HIV/AIDS- and total
healthcare cots on HIV/AIDS for each country were used.
This percentage was calculated using 2008 as base year for
all data.
Results
Figure 1 shows the flowchart for the identification of
studies with reasons for exclusion. Overall, the search
strategy identified 1,180 titles and abstracts from studies
with potential for inclusion in this review. Based on the
abstracts, 181 papers were ordered and manually reviewed.
Of these 181 articles, 26 were included in this study. See
Appendix 1 for details regarding included studies
Description of cost studies on HIV/AIDS treatment
Tables 1 and 2 contain a description of the 26 articles in-
cluded in the present study as well as the 76 cost estimates
contained in these articles, more than one paper contained
more than one cost estimate. The number of studies
published on HIV/AIDS treatment over time is as follows:
8 articles (30.8%) were published before 2000, 11 articles
first appeared between 2000 and 2004, and the remaining 7
(26.9%) were published between 2005 and 2009. The years
with the greatest research output were 1998 and 2000 (6
and 4 articles published in each of these respective years).
Of all the articles reviewed, 26.9% investigated HIV/AIDS
treatment costs in Spain (7 articles), while other countries
include Italy (7 articles), the United Kingdom (6 articles),
and France (5 articles). Only 1 of the articles was published
by Germany. Although all of the cost studies analyzed
HIV/AIDS treatment in European countries, 4 (15.38%)
were written by authors based in the United States, a
country with a long-standing tradition and experience in
HIV/AIDS research.
The sample studied herein comprises 25 of the 26 articles
accessed (96.15% of the total). Of all the cost estimates in
the articles (76 treatment costs), 21 were based on studies
that included fewer than 150 patients. The average number
of patients included in all of the studies was 1,743; the
standard deviation (SD) was near the average (2,120); the
median value was 1,127 patients. The discrepancy between
the mean and median values is due to the sample-size dis-
persion in the articles reviewed; indeed, we found patient
samples that ranged from 37 (lowest) to 6,002 (highest).
Thirty-two of the 76 cost estimates report patient ages
(average age: 31.78 years), and 40 provide information on
distribution by sex (78% males). In 28 of the 76 cost esti-
mates (36.84%), the primary means of transmission was
intravenous-drug use, while in 36.84% of the cases, the
disease was transmitted sexually. Transmissions via blood
transfusion (n = 8; 10.53%) and in patients with hemophilia
(n = 7; 9.21%) accounted for the lowest number of HIV/
AIDS infections. Fifteen of the cost estimates (19.73%)
reported average viral load values, expressed in copies
per milliliter (average viral load: 16,836.27 copies/mL, SD
17,213.01). The lowest number of copies per milliliter was
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3, and the highest was 49,069. Thirty-eight (50%) of the 76
cost estimates provided mean CD4+/mm3 lymphocyte
counts; the mean count for all observations was 290.16
CD4+/mm3, with an SD of 159.76 CD4+/mm3. The lowest
lymphocyte count in all the studies was 14 CD4+/mm3,
and the highest was 713 CD4+/mm3. The study that re-
ports a lymphocyte count of 14 CD4+/mm3 clarifies that
the patients included were in an advanced stage of the dis-
ease and had lymphocyte counts below 50 CD4+/mm3.
Only 3 of the studies provide data on median CD4 counts,
with these data appearing in 9 different estimates. All the
other reports express CD4 data as mean values.
Twenty-three of the 76 cost estimates (30.26%) do not in-
dicate the developmental stage of the illness in the patients
included. In 11.84% of the estimates, all of the patients
studied were asymptomatic, while 11.84% of the calcula-
tions were based on patients who had progressed to AIDS.
In 11 of the estimates the patients had AIDS, and in 3 the
individuals were AIDS patients who reported whether or
not they had had a previous AIDS-related event. Twenty-
Figure 1 Flowchart of study identification and selection.
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Table 1 Main characteristics of included studies
Country Author Publication
year









Spain Domingo JM et al. 1998 Oficial Journal Of The
International AIDS Society
249 No information Prevalence No information Bottom-up
Spain Velasco M et al. 2000 HIV Medicine 155 No information Prevalence No information Bottom-up
Spain Mompó C et al. 2000 Gaceta Sanitaria 109 No information Prevalence No information Bottom-up
Spain Llibre-Codina JM
et al.
2007 Enfermedades Infecciosas y
Microbiologia Clínica
1.286 Prevalence Prevalence No information Bottom-up
Spain Velasco M et al. 2007 European Journal Of Internal
Medicine
101 No information Prevalence No information Bottom-up
Spain Santolaya Perrín
et al.
2008 The Annals Of Pharmacotherapy 144 No information Prevalence No information Bottom-up
Spain Lopez-Bastida et al. 2009 BIOMEDCENTRAL Health Services
Research
572 Prevalence Prevalence Bottom-up Bottom-up
Germany Stoll M et al. 2002 Journal of Medical Research 168 (average
3 years)
No information Prevalence No information Bottom-up
France Mouton Y et al. 1997 Oficial Journal Of The International
AIDS Society
7.749 No information Prevalence No information Bottom-up
France Rahmouni S et al. 1998 International Society For
Pharmacoeconomics And
Outcomes Research
1.558 No information Prevalence No information Bottom-up
France Peyron F et al. 1999 The Journal Of Pharmacy Technology 257 No information Prevalence No information Bottom-up
France Le Pen C et al. 2001 HIV Clinical Trials 500 No information Prevalence No information Bottom-up
France Yazdapnpanah
Y et al.
2002 Antirretroviral Therapy 1.232 No information Prevalence Micro-costing Bottom-up
Italy Floridia M et al. 2000 HIV Clinical Trials 166 Incidence Incidence No information Bottom-up
Italy Garattini L et al. 2001 AIDS Care 483 No information Prevalence Micro-costing Bottom-up
Italy Sabbatini S,
Cesari R.
2002 Clinical Drug Investigation 650 No information Prevalence No information Bottom-up
Italy Torti C et al. 2003 Health Policy 1.268 (average
4 years)
No information Prevalence No information Bottom-up
Italy Tramarin A et al. 2004 Pharmacoeconomics 74 No information Prevalence No information Bottom-up
Italy Merito M et al. 2005 Health Policy 5.422 No information Prevalence No information Bottom-up
Italy Hubben GAA et al. 2008 AIDS Care 119 Prevalence Prevalence Bottom-up Bottom-up



























Table 1 Main characteristics of included studies (Continued)
United Kingdom NPMS Steering
Group.
1998 International Journal Of STD
& AIDS
6.002 Prevalence Prevalence No information Bottom-up
United Kingdom Beck EJ, Tolley K. 1998 International Journal Of STD
& AIDS
5.708 Prevalence Prevalence No information Bottom-up




No information Incidence No information Bottom-up
United Kingdom Mullins CD et al. 2000 Clinical Therapeutics 4.817 No information Prevalence No information Bottom-up























Table 2 Direct and non-direct costs variability intra country by patient (€ 2010)
Spain (n* = 9**) Germany (n* = 3) France (n* = 4**) Italy (n* = 17**)
n MEAN SD MIN MAX n MEAN SD MIN MAX n MEAN SD MIN MAX n
Healthcare costs
Antiretrovirals 9 10.248,37 4.489,01 5.883,34 20.276,09 3 18.182,24 1.132,91 17.424,92 19.317,96 4 13.152,19 3.177,05 671,51 13.974,88 17
Other drugs 3 202,40 146,39 86,10 367,11 3 5.931,71 2.222,07 4.283,57 8.153,47 1 961,37 - - - 5
Hospitalization 6 985,68 997,51 31,09 2.621,26 3 6.258,58 3.058,57 3.980,94 9.316,08 2 1.629,00 298,80 1.575,33 2.460,77 11
Primary care 6 378,85 195,62 261,23 871,22 3 488,02 249,56 231,87 719,55 4 2.468,54 820,62 182,84 5.860,8 9
Acute care 6 97,29 52,19 52,61 211,45 0 - - - - 0 - - - - 0
Diagnostic tests 3 885,13 135,76 771,29 1.021,21 3 1.263,22 171,72 1.057,01 1.396,65 0 - - - - 4
Other direct costs 2 33,24 50,66 4,78 78,33 3 104,41 26,23 84,91 130,63 1 4.099,84 - - - 10
Total heatlhcare costs *** 9 11.638,38 3.756,36 8.547,53 20.276,09 3 32.109,62 6.960,48 26.650,64 39.041,96 4 14.821,02 1.896,73 5.380,25 15.210,43 17
Non-healthcare costs
Occupational losses 3 5.661,18 1.871,58 4.045,37 7.152,04 0 - - - - 0 - - - - 3
Formal care 0 - - - - 0 - - - - 0 - - - - 0
Informal care 0 - - - - 0 - - - - 0 - - - - 0
Other non-direct costs 0 - - - - 0 - - - - 0 - - - - 0























Italy (n* = 17**) United Kingdom (n* = 15**)
MEAN SD MIN MAX n MEAN SD MIN MAX
Healthcare costs
Antiretrovirals 6.579,60 3.252,27 1.185,66 9.974,46 15 16.820,15 7.475,57 7.143,75 29.065,71
Other drugs 5.304,43 1.953,96 988,24 7.054,24 0 - - - -
Hospitalization 1.178,43 884,20 67,17 3.966,24 9 7.241,7 6.249,54 1.884,59 21.275,59
Primary care 155,18 254,24 31,22 1.571,93 0 - - - -
Acute care - - - - 0 - - - -
Diagnostic tests 1.375,87 74,90 1.341,49 1.530,34 0 - - - -
Other direct costs 713,93 1.160,36 230,55 10.111,36 9 7.060,13 4.384,84 3.245,49 13.052,02
Total heatlhcare costs *** 6.399,23 2.503,00 2.173,90 25.944,39 15 25.339,7 14.548,79 10.571,45 53.241,22
Non-healthcare costs
Occupational losses 1.353,56 609,90 788,55 1.986,69 6 5.613,33 4.564,90 1.722,51 11.962,60
Formal care - - - - 6 1.909,99 628,43 1.259,27 2.683,22
Informal care - - - - 6 1.816,30 531,32 1.451,24 2.588,28
Other non-direct costs - - - - 6 1.007,62 2.445,77 0 23.751,13
Total non-healthcare costs 1.353,56 609,90 788,55 1.986,69 6 10.347,24 7.448,33 4.443,02 23.751,13
* = number of cost estimates included in the analysis;** = In France, Spain, Italy and United Kingdom, we found 22 cost estimates, originated by 8 different studies, that: (a) did not have similar methodology than the
rest of studies, so, there were indicen studies (when most part of the studies were prevalence studies); and, (b) did not incorporate antiretrovirals costs and another type of cost (so, these studies either incorporate
antirretroviral costs or any other type of cost). For this reason, authors decided to include in this comparative intra country analysis with only 61 estimates and do not incorporate studies such as Domingo et al. (1998),
Evans et al. (2009), Floridia et al. (2000), Llibre-Codina et al. (2007), Mompó et al. (2000), Rahmouni et al. (1998), Sculpher et al. (1998) and, Yazdanpanah et al. (2002); and, *** Total healthcare costs are not equal to the
























one estimates (27.63%) used alternative means of
describing the developmental stage of the disease, such
as the CDC classification system and disease severity, or
according to whether or not they had progressed to
AIDS and whether or not they had participated in a
study that included antiretroviral therapy, or depending
on diagnostic status or per type of disease accompany-
ing AIDS, etc.
In terms of type of cost study (see Figure 2), of the 26
articles analyzed, 1 examined the cost of the adverse
effects of the treatment, and 2 of the studies analyzed the
treatment costs and independently assessed the effective-
ness of the treatment without comparing the two. How-
ever, most of the studies analyzed the cost of treatment or
the use and the cost of the resources for treating HIV/
AIDS.
Ten of the 26 articles (38.46%) specifically mentioned the
point of view from which the study was conducted. Of
these 10 articles, 7 (26.92%) examined the issue from the
perspective of funding sources, 1 analysis (3.85%) focused
on the point of view of the provider, and 2 articles (7.69%)
adopted a social perspective. In 84.61% of the articles that
did not make specific reference to the analytical perspective
employed, this information was gleaned from the details of
the text. It was not possible to ascertain the analytical
perspective in 4 of the articles. Fifty percent (n = 13) of the
articles approached the issue from the perspective of the
funding source.
Only 6 articles expressly indicate the approach used for
the cost study. One article (3.85%) focuses on incidence,
while 5 base their analysis on prevalence (19.23%). While
76.92% of the authors of the remaining articles (n = 20) did
not specify the approach used, a review of the works
revealed that 92.31% of the articles (n = 24) are based on
prevalence, while 7.69% approach the topic from the
viewpoint of incidence.
All the articles used a bottom-up approach (cost calcula-
tion progressing from most detailed to most general) for
their cost analyses, although only 19.23% of the articles
(n = 5) make explicit reference to this information. Eleven
of the articles (42.31%) used the euro as the currency of
reference for cost analyses, followed by 7 articles (26.92%)
which expressed costs in pounds sterling. Three articles
used the French franc, and 1 study used the Spanish pe-
seta. (These works predate the introduction of the euro.)
Although all the articles reviewed in the present study deal
with European countries, 4 of them (15.38%) calculated
costs in US dollars.
Costs are expressed according to pre-2000 price levels in
57.69% of the articles (n = 15), while only 5 used post-2000
prices for their calculations (23.08%). In 23.08% of the
articles (n = 6), the year used for price calculations was not
provided.Costs were expressed in daily, monthly, mean, and
annual prices per patient, although the necessary transfor-
mations and calculations were carried out to allow for
uniform, per-patient cost components. Sixty-two of the cost
estimates (81.58%) only calculated medical costs, while 6
(7.9%) only included non-medical costs. Eight of the
estimates included both cost types.
Only 65 of the 76 estimates of the cost of treating HIV/
AIDS patients (86%) specified the temporal horizon they
used. Thirteen of the studies (20%) were conducted over
more than 1 year, while 40 analyses used a 1-year temporal
horizon (61.53%). All other analyses took place over less
than 1 year. The mean (median) temporal horizon used in
the studies was 75.05 (52) weeks.
Regarding sources of funding, 15 of the 26 works pro-
vided this information. Private-sector funding was used in
26.92% of the cases (n = 7), and public-sector funding was
used in 23.08% (n = 6). Merck and GSK funded more stud-
ies than any other firms that market therapy, backing 3 and
2 studies, respectively.
Figure 2 Distribution of study types.
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Health care costs
Of the 70 estimates that calculated healthcare costs, 74.29%
used primary data sources (clinical trials) (n = 52) to obtain
information on resource use and costs. Only 12 estimates
(17.14%) used secondary data sources (data gathered from
bibliographical references or published studies). The
remaining 6 estimates (8.57%) used a combination of
primary and secondary sources for their data.
Concerning medical costs, 67 of the 70 estimates made
specific reference to the type of direct costs studied. Fifty-
nine estimates referred to the costs of antiviral medica-
tions (77.63%), 48 reports included hospitalization costs
(63.16%), and 42 (55.26%) detailed the costs of primary
and outpatient care. The cost of diagnostic tests is analyzed
in 27.63% of the estimates (n = 18), and 7.89% (n = 6)
analyze the cost of emergency care. The total health care
costs are those specified and calculated in the study. Some
of these cost calculations are the sum of the columns
containing the different cost items, although at times this is
not the case.
Non-health care costs (lost working time and costs of formal
and informal care)
Of the 14 estimates of non-healthcare costs, 8 (57.14%)
used primary sources to gather data on resource use and
costs, and 6 other estimates (42.86%) used an approach that
combined primary and secondary sources. In 85.71% of the
estimates of non-health care costs (n = 12), the calculations
include lost work time in HIV/AIDS patients, while the
remaining 2 estimates compute the costs of formal (paid)
and informal (unpaid) care required by these patients. The
total non-health care costs are those specified and calcu-
lated in the study. Some of these cost calculations are
arrived at by adding together the columns containing the
different cost items, although at times this is not the case.
Primary country-specific costs: intra- and inter-country
variability
The mean estimated annual cost of HIV/AIDS treatment in
the European countries described as part of this study
appears in Table 3. To allow for proper comparison, the
results appearing in this table were obtained from studies
adopting a similar methodology. All of the figures have
been updated by taking 2010 as a reference year. The
primary findings are as follows:
In Spain, the estimated treatment cost per patient-year is
€11,638, with an SD of €3,756. The approximate annual
cost of treating these patients in Germany is €32,110 (SD
€6,960). For France, the estimated per-person annual treat-
ment cost is €14,821 (SD €1,897). HIV/AIDS treatment in
Italy costs an average of about €6,399 per patient (SD
€2,503). Lastly, it was found that the mean cost of this
treatment per patient-year in the United Kingdom was
€25,340 (SD €14,549).
The results appearing in Table 3 demonstrate a high de-
gree of inter-country variability, with Spain, France, and
Italy showing substantially lower annual per-patient costs
than those found for Germany and the United Kingdom.
Studies carried out in different countries using similar
methodologies produced similar findings in this regard,
indicating that drugs—mainly antiretroviral medications—
are the primary medical-care cost component, followed by
hospitalization costs, costs for outpatient and primary-
care consultations, and the costs of diagnostic tests.
In terms of health care costs, the lowest cost of antiretro-
viral treatment was found in Italy, followed by Spain and
France. It was observed that the cost of medications in
Germany and the United Kingdom are well above those of
the 3 aforementioned countries. It must also be pointed out
that hospitalization costs are much lower in Spain than in
the rest of the countries studied, and a significant difference
was observed between inpatient-care costs in Spain, Italy,
and France compared to those in Germany and the United
Kingdom.
In light of the great disparity of medical-care costs
between countries, the country-specific costs incurred were
calculated, and these can be seen in Table 4. These data
indicate which stage of the disease is being treated and the
lymphocyte counts of the patients receiving the treatment.
The only country in which the studies reviewed included
disease-phase information is the United Kingdom; the
absence of this information for all the other countries is
noteworthy. We can only state that in Spain and the
United Kingdom, total medical-care costs rise progressively
in step with increasing disease stages. Results according to
the lymphocyte counts of patients are also presented. The
United Kingdom and Italy are the 2 countries that provide
the most detailed information on this indicator. The lack
of such information from the rest of the countries is once
again noteworthy. In the United Kingdom and Italy, a
progressive cost increase is seen in patients with lower
lymphocyte counts, that is, patients who are more suscep-
tible to have other illnesses. There is also a great disparity
in total medical costs for patients with lymphocyte counts
between 200 CD4+/ mm3 and 500 CD4+/ mm3, although
the reason for this variation is unclear.
We carried out an analysis to establish whether a link ex-
ists between higher total care costs and greater number of
years elapsed since the calculation of these costs, although
no such link was found. Inter-country differences in total
care costs may be caused by price differences, differing fre-
quency of hospital use, or the cost of medications; however,
more information would be required from the authors of
the different studies in order to reach a conclusion.
The results of the works analyzed together with informa-
tion on medical-care spending and official figures of HIV/
AIDS prevalence in the 5 countries studied were extrapo-
lated in order to estimate the total annual cost of treating
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Table 3 Direct and non-direct costs variability intra country per patient according to phase of the disease and lymphocytes level (€ 2010)
Total healthcare
costs
Spain (n* = 9) Germany (n* = 3) France(n* = 4) Italy (n* = 17)
n MEAN SD MIN MAX n MEAN SD MIN MAX n MEAN SD MIN MAX n
According to phase of the disease (**)
Asymptomatic phase 1 8.547,53 - - - 0 - - - - 0 - - - - 1
Symptomatic phase 1 10.173,81 - - - 0 - - - - 0 - - - - 0
AIDS phase 2 11.032,38 1.058,39 10.272,01 11.768,99 0 - - - - 0 - - - - 1
According to lymphocytes level (CD4 cells)
CD4s < 200 0 - - - - 0 - - - - 0 - - - - 3
200 < CD4s < 500 3 9.922,42 750,11 8.849,42 10.272,01 3 32.109,62 6.960,48 26.650,64 39.041,96 1 13.396,55 - - - 2

























Italy (n* = 17) United Kingdom (n* = 15)
MEAN SD MIN MAX n MEAN SD MIN MAX
According to phase of the disease (**)
Asymptomatic phase 2.173,9 - - - 5 1.4991,73 3.493,29 10.571,45 18.290,76
Symptomatic phase - - - - 5 19.222,25 4.437,73 12.131,42 22.945,24
AIDS phase 15.182,96 - - - 5 42.968,55 12.487,71 23.155,18 53.241,22
According to lymphocytes level (CD4 cells)
CD4s < 200 19.252,63 5.840,26 15.182,96 25.944,39 3 49.326,37 6.250,58 42.117,73 53.241,22
200 < CD4s < 500 12.227,88 2.062,68 9.670,24 13.059,63 9 21.445,86 9.572,81 11.889,08 45.811,29
CD4s > 500 6.399,34 2.369,71 2.173,9 10.363,14 0 - - - -























people with HIV/AIDS. Since the data available on preva-
lence are from 2007 [20], and since data on medical-care
costs as a percentage of gross domestic product are avail-
able only up to 2008, an estimate was made using 2008 as
the base year, as the prevalence figures showed slight year-
to-year variation. Table 5 contains the total estimated med-
ical costs for each country as well as the percentage
devoted to HIV/AIDS treatments relative to overall med-
ical spending. This estimate was calculated by applying
the conservative scenario by which it is assumed that 25%
of HIV-positive individuals are unaware that they are
infected and, therefore, are not receiving treatment.
According to our calculated average healthcare cost of
treatments of HIV/AIDS resulting from the quantitative
analysis, the cost of HIV/AIDS in Spain represents 1.25%
of overall medical-care spending, while total HIV/AIDS-
treatment spending amounts to 0.49% in Italy, 0.52% in
France, and 0.9% in the United Kingdom. In Germany,
despite the country’s low HIV/AIDS prevalence, 0.48% of
total medical-care spending is devoted to treating the
disease. When compared to other health problems, these
figures are high given the low prevalence of HIV/AIDS in
terms of population. If we consider that almost all of the
medical-care spending for HIV/AIDS treatment in Spain
is publicly funded, the percentage of HIV/AIDS medical
costs rises to 1.73% of the total public-sector spending.
Discussion and conclusions
Despite the evidence demonstrating that the social and eco-
nomic cost of HIV/AIDS is quite substantial, there are still
areas where knowledge of this issue is scant. This review
contributes in analysing the effort done in the last decade
to measure the cost of illness of this disease and highlights
the way forward for advancing in this area. There is a great
paucity of information available on the non-medical costs
incurred due to HIV/AIDS treatment. The non-medical
cost components that were identified and assigned a mon-
etary value comprised lost working time, formal and infor-
mal care, and disability payments. Although no studies of
this nature have been carried out in France or Germany, re-
search in Spain, Italy, and the United Kingdom has revealed
that while these values are lower than medical-care costs,
they are substantial sums nonetheless.
While there appears to be little doubt that prolonging the
life expectancy of carriers of the virus who live in high-
income countries increases the cost of treating each patient
throughout his or her life, there is still no international con-
sensus on whether or not the advances made in treating
the disease have increased the annual cost of caring for
these individuals. These costs may vary significantly from
one country to another, and there may be great inter-
country disparity in the economic impact of HIV/AIDS
treatment depending on the unit costs of the treatment as
well as the epidemiology of the disease in a given country.
Aside from the health care costs of HIV/AIDS treatment, a
number of social costs exists which may have a substantial
impact on studies of the disease, such as lost work time in
HIV-infected individuals.
The studies reviewed for the present work point to a sub-
stantial variation in the cost of treating patients with HIV/
AIDS since the advent of highly active antiretroviral therapy
(HAART). Our endeavor to properly compare the estimates
published—including the different cost items factored into
care costs—was a complex task due to the inconsistencies
in the components included as well as the lack of explicit
information in the articles. These difficulties appear to be
common in the literature on HIV/AIDS. Indeed, Levy et al.
[26] came to a similar conclusion in their review article on
the medical-care costs of HIV/AIDS.
In the comprehensive review by Beck et al. [3], the
authors highlight the need to increase the body of evidence
that can be used to more accurately estimate the overall
economic impact of HIV/AIDS infection. The authors
found only 3 studies published after 1996. The present
article, however, which focuses on the European context,
analyzes 26 articles. This number is indicative of the great
Table 4 People who live with HIV/AIDS
Year 2007 Base Lower quote Upper quote
Spain 140.000 80.000 230.000
Germany 53.000 31.000 97.000
France 140.000 78.000 240.000
Italy 150.000 110.000 210.000
United Kingdom 77.000 37.000 160.000
Source: ONUSIDA, 2008.
Table 5 Total healthcare cost of treatments of HIV/AIDS and% of the total health cost from each country (€2008)
Total healthcare costs (million€) Healthcare cost as a % of the total health cost
Base Lower quota Higher quote Base Lower quota Higher quota
Spain 1.222,16 698,38 2.007,84 1,25% 0,72% 2,06%
Alemania 1.253,89 733,40 2.294,85 0,48% 0,28% 0,88%
France 1.124,74 626,64 1.928,12 0,52% 0,29% 0,88%
Italy 695,07 509,72 973,10 0,49% 0,36% 0,68%
United Kingdom 1.406,57 675,89 2.922,75 0,90% 0,43% 1,86%
Source: Own elaboration from the data provided by different sources.
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effort and the high interest in estimating the global cost of
this illness.
The methodological approach used in the articles
reviewed is predominantly bottom-up (i.e., based on patient
samples), as there are scant sources of reference (e.g., regis-
tries, databases) of a national or international scope which
would allow for a top-down approach to be used.
In addition, most studies approach the issue by focusing
on prevalence; incidence-based studies are more scarce.
This result is common in cost of illness studies in other
areas of treatment, as incidence-based approaches have
more stringent requirements regarding the information
needed to carry out the analysis; indeed, incidence-based
studies require life-expectancy and cost estimates incurred
throughout the natural course of the disease.
It must be pointed out that the figures appearing in
Table 3 do not include all of the studies reviewed, but
rather those that employ a comparable methodological ap-
proach. The reason for this is, on the one hand, the differ-
ent objectives and study designs of the works reviewed, and
on the other, the fact that the methodological approaches
used in HIV/AIDS cost-of-illness studies have improved.
Regarding the first reason, it would be unreasonable to
compare incidence-based and prevalence-based studies, just
as it would be unreasonable to compare studies that focus
on the cost of treating adverse effects (very concrete object-
ive) to HIV/AIDS cohort studies that seek to determine the
costs incurred throughout the study period (more general
objective). As for the second reason, there is ample room
for improvement in the studies revised, as many of them
fail to adequately detail such essential elements as an expli-
cit description of the vantage point used (e.g., social, fund-
ing, provider), the approach (e.g., incidence, prevalence),
and other methodological aspects. In addition, the cost
components are not uniformly disaggregated, and one can
find some studies in which pharmaceutical treatment is in-
cluded under hospital care, while others compute drug
therapy under outpatient resources. Such methodological
heterogeneity increases the difficulty of conducting inter-
study comparisons.
While the number of studies on the medical costs (direct
costs) of HIV/AIDS treatment has increased considerably,
the present work has found that few publications take non-
medical costs into account. In their 2004 study, Liu et al.
[37] emphasized the need for studies that include non-
medical aspects, although in the years since their work the
output of this type of research has continued to be low.
Although few studies have set out to estimate the non-
medical costs of HIV/AIDS in high-income countries
(mainly lost work time but also the cost of formal and
informal care), it is worth noting that other works have
highlighted the substantial impact that HIV/AIDS had on
work engagement among carriers of the disease in the years
before effective treatments were made available [27-30].
Also, later studies have clearly indicated that the advances
in therapy that have been achieved since the mid-1990s
have had a major impact on this issue, and a number of
studies have published evidence of this effect [6,31-35].
These studies have not been included in the present review
since they provide information on changes in the probabil-
ity of being employed of HIV + people without assigning a
monetary value to this change. However, we should stress
that the aforementioned studies report improvements in
the labor situation of people with HIV/AIDS, this does not
mean that the general population has also experienced such
an improvement. Significant differences exist between the 2
groups, and these differences are more pronounced at
greater levels of health deterioration, and differences also
exist in terms of the patterns or habits of the individuals
studied as revealed by the means through which they were
infected [6,38].
In summary, this review shows the profound impact
that HIV/AIDS-treatment costs have in the countries
studied. Our study also shows that the methodology used
in many of the studies carried out in this field leaves
ample room for improvement. Lastly, although there has
been a marked increase in the number of investigations
on medical-care costs in recent years, there is still a
great amount of work to be done toward applying the
social perspective to these cost analyses [39]. In addition
to calculating the medical and non-medical costs associ-
ated with HIV/AIDS, studies of this nature should reflect
the social burden that lies outside the healthcare realm
but which nonetheless is borne by persons who are not
carriers of the disease. The impact of this disease may fall
on society as a whole.
Appendix 1. Papers included in the systematic
literature review (26 papers)
Beck EJ, Tolley K: Financing HIV service provision in
England: estimated impact of the cost of antirretroviral
combination therapy. International Journal of STD &
AIDS 1998, 9(9):512–517.
Beck EJ, Tolley K, Power A, Mandalia S, Rutter P, Izumi J,
Beecham J et al.: The use and cost of HIV service
provision in England in 1996. Pharmacoeconomics 1998,
14(6): 639–652.
Domingo JM, Guardiola J, Ris J, Nolla J: The impact of
new antirretroviral regimes on HIV-associated hospital
admissions and deaths. AIDS 1998, 12(5):529–543.
Evans HER, Tsourapas A, Mercer CH, Rait G, Bryan S,
Hamill M, et al.: Primary care consultations and costs
among HIV-positive individuals in UK primary care
1995–2005: a cohort study. Sexually Transmitted Infections
2009, 85(7):543–549.
Floridia M, Massella M, Bucciardini R, Perucci CA,
Rossi L, Tomino C et al.: Hospitalizations and costs of
treatment for protease inhibitor-based regimens in
Trapero-Bertran and Oliva-Moreno Health Economics Review 2014, 4:15 Page 14 of 16
http://www.healtheconomicsreview.com/content/4/1/15
patients with very advanced HIV-infection (CD4 < 50/
mm3). HIV Clinical Trials 2000, 1(2):9–16.
GarattiniL, Tediosi F, Di Cintio E, Yin D, Parazzini F:
Resource utilization and hospital cost of HIV/AIDS
care in Italy in the era of highly active antirretroviral
therapy. AIDS Care 2001, 13(6):733–741.
Hubben GAA, Bishai D, Pechlivanoglou P, Cattelan AM,
Grisetti R, Facchin C, et al.: The societal burden of HIV/
AIDS in Northern Italy: An analysis of costs and quality
of life. AIDS Care 2008, 20(4) :449–455.
Le Pen C, Rozenbaum W, Downs A, Maurel F, Lilliu H,
Brun C: Effect of TARGA on health status and hospital
costs of severe HIV-infected patients: a modeling
approach. HIV Clinical Trials 2001, 2(2):136–145.
Llibre-Codina JM, Casado-Gomez MA, Sánchez-de la
Rosa R, Pérez-Elías MJ, Santos-González J, Miralles-
Álvarez C et al.: Costes de la toxicidad asociada a los
análogos de nucleósidos inhibidores de la transcriptasa
inversa en pacientes con infección por el VIH-1.
Enfermedades Infecciosas y Microbiologia Clínica 2007,
25(2): 98–107.
Lopez-Bastida J, Oliva-Moreno J, Perestelo-Perez Ll,
Serrano-Aguilar P: The economic costs and health-
related quality of life of people with HIV/AIDS in he
Canary Islands, Spain. BMC Health Services Research
2009, 9:55–63.
Merito M, Bonaccorsi A, Pammolli F, Riccaboni M,
Baio G, Arici C, et al.: Economic evaluation of HIV
treatments: The I.C.O.N.A. cohort study. Health Policy
2005, 74(3):304–313.
Mompó C, Abbas I, Santín M, Rovira J, Antón F, Tomás C,
et al.: La utilización de recursos sanitarios en
pacientes infectados por el virus de la immunodefi-
ciencia humana: creación de una base de datos y
obtención de resultados de costes. Gaceta Sanitaria
2000, 14(1):39–47.
Mouton Y, Alfandari S, Valette M, Cartier F, Dellamonica P,
Humbert G et al.: Impact of protease inhibitors on
AIDS-defining events and hospitalizations in 10 French
AIDS reference centres. AIDS 1997, 11(12):101–105.
Mullins CD, Whitelaw G, Cooke JL, Beck EJ: Indirect
cost of HIV infection in England. Clinical Therapeutics
2000, 22(11):1333–1345.
NPMS Steering Group: Changing cost of English HIV
service provision 1996–1997. International Journal of
STD & AIDS 1999, 10(6):357–362.
Peyron F, Rahmouni S, Flori A, Moreau J, Charbit J-J,
Buès-Charbit M, et al.: Impact of protease inhibitors
on drug use and cost for hospital patients with HIV.
Journal of Pharmacy Technology 1999, 15(6):212–218.
Rahmouni S, Peyron F, Flori A, Moreau J, Charbit JJ,
BuesCharbit M, Balansard G: Pharmacoeconomic
efficiency of the use of protease inhibitors for
hospital inpatients with AIDS. ISPOR, Inaugural
European Conference (Cancer and Aids). 1998.
Cologne, Germany.
Sabbatani S, Cesari R: Cost assessment of antir-
retroviral drugs used in the treatment of patients with
HIV infection. Focus on non-nucleoside reverse tran-
scriptase inhibitors. Clinical Drug Investigation 2002,
22(4):253–262.
Santolaya Perrín R, García López FJ: Incremental drug
treatment cost in HIV-positive patients in industry-
sponsored clinical trials. The Annals of Pharmacotherapy
2008, 42(11):1586–1591.
Sculpher MJ, Gibb D, Ades AE, Ratcliffe J, Duong T:
Modelling the costs of paediatric HIV infection and
AIDS: comparison of infected children born to screened
and unscreened mothers. AIDS 1998, 12(11):1371–1380.
Stoll M, Claes C, Schulte E, Graf von der Schulenburg
JM, Schmidt RE: Direct costs for the treatment of HIV-
infection in a German cohort after the introduction of
TARGA. European Journal of Medical Research 2002,
7(11):463–471.
Torti C, Casari S, Palvarini L, Quiros-Roldan E, Moretti F,
Leone L, et al.: Modifications of health resource-use in
Italy after the introduction of highly active antirretro-
viral therapy (TARGA) for human immunodeficiency
virus (HIV) infection. Pharmacoeconomic implications
in a population-based setting. Health Policy 2003,
65(3):261–267.
Tramarin A, Campostrini S, Postma MJ, Calleri G, Tolley
K, Parise N et al.: A multicentre study of patient survival,
disability, quality of life and cost of care. Among pa-
tients with AIDS in Northern Italy. Pharmacoeconomics
2004, 22(1):45–53.
Velasco M, Gómez A, Fernández C, Pérez-Cecilia E,
Téllez MJ, Roca V, et al.: Economic impact of HIV prote-
ase inhibitor therapy in the global use of health-care
resources. HIV Medicine 2000, 1(4):246–251.
Velasco M, Losa JE, Espinosa A, Sanz J, Gaspar G,
Cervero M, et al.: Economic evaluation of assistance to
HIV patients in a Spanish hospital. European Journal of
Internal Medicine 2007, 18(5):400–404.
Yazdanpanah Y, Goldie SJ, Losina E, Weinstein MC,
Lebrun T, Paltiel AD, et al.: Lifetime cost of HIV care in
France during the era of highly active antirretroviral
therapy. Antirretroviral Therapy 2002, 7(4):257–266.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MTB carried out the literature review, the main cost analysis and drafted the
manuscript. JO participated in the cost analysis, drafting the discussion and
reviewed the manuscript. Both authors read and approved the final manuscript.
Acknowledgements
The authors would like to acknowledge the support received from the
research project ECON2013-48217-C2-2-R “Impacto económico, sanitario y
social de las enfermedades y los problemas de salud: información y
herramientas para la evaluacion de políticas públicas.
Trapero-Bertran and Oliva-Moreno Health Economics Review 2014, 4:15 Page 15 of 16
http://www.healtheconomicsreview.com/content/4/1/15
Author details
1University Pompeu Fabra, Department of Economics and Business, Centre
for Research on Economics and Health, Ramon Trias Fargas 25-27, Barcelona
08005, Spain. 2University Castilla La-Mancha, Facultad de Terapia
Ocupacional, Logopedia y Enfermería, Avda. Real Fábrica de Seda, s/n,
Talavera de la Reina, Toledo 45600, Spain. 3Facultad de Ciencias Jurídicas y
Sociales, Análisis Económico y Finanzas, Cobertizo de San Pedro Mártir s/n,
Toledo 45071, Spain.
Received: 4 April 2014 Accepted: 22 July 2014
References
1. Fauci AS: The AIDS Epidemic. Considerations for the 21st Century. N Engl
J Med 1999, 341:1046–1050.
2. Ojo K, Delaney M: Economic and demographic consequences of AIDS in
Namibia: rapid assessment of the costs. Int J Health Plann Manage 1997,
12(4):315–326.
3. Beck EJ, Miners AH, Tolley K: The cost of HIV treatment and care. A global
review. Pharmacoeconomics 2001, 19(1):13–39.
4. International Labour Organization (ILO): El VIH/SIDA y el mundo del
trabajo. Conferencia Internacional del Trabajo, 98a reunión. In Ginebra,
Informe IV (1). 2009. (disponible en http://www.ilo.org/public/portugue/
region/eurpro/lisbon/pdf/vihsida_spa.pdf).
5. Hellinger FJ: Economic Models of Antirretroviral Therapy: Searching for
the Optimal Strategy. Pharmacoeconomics 2006, 24(7):631–42.
6. Oliva J: Labour participation of Spanish people living with HIV between
2001–2004. Health Econ 2010, 19:491–500.
7. Mooser V, Carr A: Antirretroviral therapy-associated hyperlipidaemia in
HIV disease. Curr Opin Lipidol 2001, 12(3):313–9.
8. Mallon PW, Cooper DA, Carr A: HIV-associated lipodystrophy. HIV Med
2001, 2(3):166–73.
9. Grupo VIHVIR+: Estudio epidemiológico retrospectivo sobre la duración
del tratamiento de la infección por el virus de la inmunodeficiencia
humana en España. Med Clin (Barc) 2002, 119(19):721–724.
10. Carr A, Cooper DA: Adverse effects of antirretroviral therapy. Lancet 2000,
356(9239):1423–30.
11. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, Ferraro T, Concia E:
Fulminant hepatitis associated with hepatitis A virus superinfection in
patients with chronic hepatitis C. N Engl J Med 1998, 338(5):286–90.
12. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT,
Holmberg SD, HIV Outpatient Study Investigators: Mortality in the Highly
Active Antirretroviral Therapy Era: Changing Causes of Death and
Disease in the HIV Outpatient Study. J Acquir Immune Defic Synd 2006,
43(1):27–34.
13. Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K: Increasing burden of
liver disease in patients with HIV infection. Lancet 2011, 377(9772):1198–209.
14. Blas-Garcia A, Esplugues JV, Apostolova N: Twenty Years of HIV-1 Non-
Nucleoside Reverse Transcriptase Inhibitors: Time to Reevaluate their
Toxicity. Curr Med Chem 2011 [Epub ahead of print].
15. Instituto de Salud Carlos III: Ministerio de Sanidad y Economía, Vigilancia
epidemiológica del Sida en España. In Sistema Autonómicos de vigilancia
epidemiológica. 2012. Disponible en http://www.isciii.es/ISCIII/es/contenidos/
fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-enfermedades/fd-sida/
Informe-VIH-sida-Junio-2012.pdf.
16. Lampe FC, Gatell JM, Staszewski S, Johnson MA, Pradier C, Gill MJ, de Lazzari E,
Dauer B, Youle M, Fontas E, Krentz HB, Phillips AN: Changes over time in risk
of initial virological failure of combination antiretroviral therapy: a
multicohort analysis, 1996 to 2002. Arch Intern Med 2006, 166(5):521–8.
17. Achhra AC, Phanuphak P, Amin J: Long-term immunological outcomes in
treated HIV-infected individuals in high-income and low-middle income
countries. Curr Opin HIV AIDS 2011 [Epub ahead of print].
18. Ledergerber B, Cavassini M, Battegay M, Bernasconi E, Vernazza P, Hirschel B,
Furrer H, Rickenbach M, Weber R, the Swiss HIV Cohort Study (SHCS):
Trends over time of virological and immunological characteristics in the
Swiss HIV Cohort Study. HIV Med 2011, 12(5):279–288. 10.1111/j.1468-
1293.2010.00880.x. Epub 2010 Oct 18.
19. Puhan MA, Van Natta ML, Palella FJ, Addessi A, Meinert C, Ocular
Complications of AIDS Research Group: Excess mortality in patients with
AIDS in the era of highly active antiretroviral therapy: temporal changes
and risk factors. Clin Infect Dis 2010, 51(8):947–56.
20. European Centre for Disease Prevention and Control (ECDC)/WHO Regional
Office for Europe: HIV/AIDS surveillance in Europe 2008. Stockholm: European
Centre for Disease Prevention and Control; 2009.
21. Kahn JG, Marseille E: Fighting global AIDS: the value of cost-effectiveness
analysis. AIDS 2000, 14(16):2609–10.
22. Beck EJ, Mandalia S, Gaudreault M, Brewer C, Zowall H, Gilmore N, Klein MB,
Lalonde R, Piche A, Hankins CA: The Cost-effectiveness of Highly Active
Antirretroviral Therapy., Canada 1991–2001. AIDS 2004, 18(18):2411–8.
23. Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, Weinstein
MC, Seage GR 3rd, Moore RD, Freedberg KA: The Lifetime Cost of Current
Human Immunodeficiency Virus Care in the United States. Med Care
2006, 44(11):990–7.
24. King JT Jr, Justice AC, Roberts MS, Chang CC, Fusco JS, Collaboration in HIV
Outcomes Research-US Program Team: Long-term HIV/AIDS Survival
Estimation in the Highly Active Antirretroviral Therapy Era. Med Decis
Making 2003, 23(1):9–20.
25. Keiser P, Nassar N, Kvanli MB, Turner D, Smith JW, Skiest D: Long-term
Impact of Highly Active Antirretroviral Therapy on HIV-related Health
Care. J Acquir Immune Defic Syndr 2001, 27(1):14–9.
26. Levy AR, James D, Johnston KM, Hogg RS, Harrigan PR, Harrigan BP, Sobolev B,
Montaner JS: The Direct Costs of HIV/AIDS Care. Lancet Infect Dis 2006,
6(3):171–7.
27. Scitovsky AA, Rice DP: Estimates of the direct and indirect costs of
acquired immunodeficiency syndrome in the United States, 1985, 1986,
and 1991. Public Health Rep 1987, 102(1):5–17.
28. Yelin EH, Greenblatt RM, Hollander H, McMaster JR: The impact of
HIV-related illness on employment. Am J Public Health 1991, 81(1):79–84.
29. Leigh JP, Lubeck DP, Farnham P, Fries JF: Potential and actual workdays
lost among patients with HIV. J Acquir Immune Defic Syndr Hum Retrovirol
1995, 8(4):392–8.
30. Laursen E, Larsen L: Socio-economic status of AIDS patients. Scand J Soc
Med 1995, 23(3):189–92.
31. Dray-Spira R, Lert F, Marimoutou C, Bouhnik AD, Obadia Y: Socio-economic
conditions, health status and employment among persons living with
HIV/AIDS in France in 2001. AIDS Care 2003, 15(6):739–48.
32. Rabkin JG, McElhiney M, Ferrando SJ, Van Gorp W, Lin SH: Predictors of
employment of men with HIV/AIDS: a longitudinal study. Psychosom Med
2004, 66(1):72–8.
33. Goldman DP, Bao Y: Effective HIV treatment and the employment of HIV
(+) adults. Health Serv Res 2004, 39(6 Pt 1):1691–712.
34. Bernell SL, Shinogle JA: The relationship between HAART use and
employment for HIV-positive individuals: an empirical analysis and policy
outlook. Health Policy 2005, 71(2):255–64.
35. Sendi P, Brouwer WB, Bucher HC, Weber R, Battegay M, the Swiss HIV
Cohort Study: When time is more than money: The allocation of time
between work and leisure in HIV-infected patients. Soc Sci Med 2007,
64(11):2355–61.
36. World Bank: International Monetary Fund (IMF). In World Economic and
Financial Surveys, World Economic Outlook Database. Washington D.C. USA:
IMF; 2010. Disponible en https://www.imf.org/external/pubs/ft/weo/2010/
02/weodata/index.aspx.
37. Mulligan J, Fox-Rushby J, Adam T, Johns B, Mills A: Unit costs of health care
inputs in low and middle income regions. In Disease Control Priorities
Project 2003, Working Paper No 9. Available from: http://r4d.dfid.gov.uk/
Output/170553/Default.aspx.
38. Liu GG, Guo JJ, Smith SR: Economic costs to business of the HIV/AIDS
epidemic. Pharmacoeconomics 2004, 22(18):1181–1194.
39. Lopez-Bastida J, Oliva-Moreno J, Perestelo-Perez L, Serrano-Aguilar P: The
economic costs and health-related quality of life of people with HIV/
AIDS in the Canary Islands, Spain. BMC Health Serv Res 2009, 9:55–63.
doi:10.1186/s13561-014-0015-5
Cite this article as: Trapero-Bertran and Oliva-Moreno: Economic impact
of HIV/AIDS: a systematic review in five European countries. Health
Economics Review 2014 4:15.
Trapero-Bertran and Oliva-Moreno Health Economics Review 2014, 4:15 Page 16 of 16
http://www.healtheconomicsreview.com/content/4/1/15
